Article citationsMore>>

Blom, D.J, Hala, T., Bolognese, M., Lillestol, M.J., Toth, P.D., Burgess, L., et al. (2014) A 52-Week Placebo-Controll ed Trial of Evolocumab in Hyperlipidemia. The New England Journal of Medicine, 370, 1809-1819.
http://dx.doi.org/10.1056/NEJMoa1316222

has been cited by the following article:

• TITLE: The Application of the LDL Principle

  AUTHORS: David S. Schade, Brendan Cavanaugh, Barry Ramo, R. Philip Eaton

  KEYWORDS: LDL Principle, Atherosclerosis, Myocardial Infarction, Atherosclerosis Reversal, LDL Cholesterol

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.6 No.5, May 20, 2016

  ABSTRACT: The LDL Principle has recently been invoked to describe the observation that lowering the LDL cholesterol (by whatever means) results in a lowering of atherosclerotic cardiovascular events. The scientific basis of the LDL Principle dates back to the discovery that the LDL receptor is the prime determinant of the circulating LDL-c concentration. Since that time, major advances have been made at both the basic and clinical science level in our understanding of the pathogenesis and reversal of atherosclerosis. The incorporation of atherogenic lipoproteins plus inflammatory mediators into plaque formation permits the targeted intervention into preventing plaque rupture. In addition, genetic studies identifying individuals with unique phenotypes of either abnormally high or low LDL-c concentrations have provided insight into possible therapeutic modalities that have recently provided the physician with the tools necessary to apply the LDL Principle to achieve reversal of atherosclerosis. The epidemic of atherosclerotic cardiovascular disease has resulted in numerous randomized controlled intervention trials in an attempt to identify approaches to reduce ASCD morbidity and mortality. Recently published data indicate that circulating LDL-c levels of 50 mg/dl or less are not only physiologic at birth but also effective in greatly reducing cardiovascular disease. In addition, the recent availability of two PCSK9 inhibitors provides the primary care physician with the possibility of achieving this low level of LDL-c even in statin intolerant patients. The widespread availability of the coronary artery calcium scan plus the inclusion of traditional cardiovascular risk factors in risk assessment has enabled the physician to readily identify asymptomatic individuals at high risk for cardiovascular events. Aggressively applying the LDL Principle to these individuals has the potential of greatly reducing cardiovascular mortality. This review will document the scientific basis for this principle and provide the arguments in favor of its aggressive application.